Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Rising nursing home population in APAC likely to increase spread of respiratory syncytial virus in elderly, says GlobalData

Respiratory syncytial virus (RSV), a common respiratory infection in children, has increasingly been identified as a leading cause of respiratory disease in the elderly. Continuing rates of aging and increased access to community living in long-term care facilities may increase the spread of RSV among the elderly across the Asia-Pacific (*APAC) region, according to GlobalData, […]
Read more

Case for Orchard Therapeutics’ gene therapy gets stronger with receipt of accelerated assessment from EMA, says GlobalData

Following the news that European Medicines Agency (EMA) granted accelerated assessment of OTL-200; Vinie Varkey, Senior Analyst of Neurology and Ophthalmology at GlobalData, a leading data and analytics company, offers her view on the implications of this trial for the MLD market: “With Orchard Therapeutics’ OTL-200 receiving the accelerated assessment, it is now more likely […]
Read more

Personalized medicines may improve identification of optimal treatment but access to these treatments may be difficult, says GlobalData

‘Personalized medicine’ and ‘precision medicine’ are both defined as using a patient’s genomic and phenotypic data to find targeted therapies. These therapies use a proactive approach, increase patient stratification and targeting, and aim to improve outcomes for healthcare players, according to GlobalData, a leading data and analytics company. GlobalData’s latest thematic report, ‘The State of Personalized/Precision […]
Read more

CPhI Worldwide Frankfurt to feature contributions from Fiona Barry, Peter Shapiro and Bonnie Bain from GlobalData

This year’s CPhI Worldwide pharma event in Frankfurt, Germany, will take place from 5-7 November 2019. It will feature presentations by Bonnie (Bornadata) Bain, Global Head and Executive Vice-President of Healthcare Operations & Strategy at GlobalData, alongside Fiona Barry and Peter Shapiro, Editors at PharmSource, a GlobalData product. Bonnie Bain, Global Head and Executive Vice-President of Healthcare Operations and Strategy, GlobalData […]
Read more

Hope for cancer patients, as the development of immuno-oncology therapies continues to grow globally according to Cancer Research Institute study leveraging data from GlobalData

The number of immuno-oncology (IO) therapies in clinical development and volume of clinical investigations testing these therapies for the treatment of cancer patients continue to grow, and will undoubtedly fulfill unmet needs in both hematological cancers and solid tumors over the next five to ten years. Leveraging data from GlobalData’s Pharma Intelligence platform, an Immuno-oncology Landscape update from […]
Read more

Gene therapy development expected to pick up pace, says GlobalData

Ongoing collaborations between different industry players and a buildup of real-world evidence establishing safety and efficacy are expected to drive the growth of gene therapies for neurology indications. Data and analytics company GlobalData’s latest report, ‘Gene Therapy in Neurology’, highlights that, of the 38 pipelines products that are currently in development, 45% are adeno-associated virus […]
Read more

ICER provides vote of confidence to AbbVie’s Rinvoq as it makes substantial leap in cost-effectiveness, says GlobalData

Following the news that ICER has published its latest draft of the evidence report, ‘Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value’; Rose Joachim, Pharmaceutical Analyst at GlobalData, a leading data and analytics company, offers her view: “Following the surprise withdrawal of ICER’s initial draft evidence report last month, the organization’s latest draft, published […]
Read more

North America leads in number of strategic pharma partnerships between 2014 and H1 2019

From 2014 to the first half (H1) of 2019, there were more than 1,300 separate strategic partnerships and 1,000 licensing agreements made in the global pharmaceutical industry that involved gene therapy, immuno-oncology, microbiome and orphan drug therapeutics, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Deal-Making Trends in Pharma – […]
Read more

Deal activity remains vibrant within the pharmaceutical industry between 2014 and H1 2019

From 2014 to the first half (H1) of 2019, the pharmaceutical and healthcare industry recorded 2,882 deals that fell within the gene therapy, immuno-oncology, microbiome and orphan drug space. Comprising strategic partnerships, licensing agreements and mergers and acquisitions (M&As), these deals were worth $1,068.8bn in total, according to GlobalData, a leading data and analytics company. […]
Read more

M&A activity within the pharmaceutical industry remains high in H1 2019

From 2014 to the first half (H1) of 2019, the global pharmaceutical industry saw more than 400 mergers and acquisitions (M&A) in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic categories. The M&As that involved immuno-oncology and/or orphan drug assets continue to dominate this deal space, according to GlobalData, a leading data and analytics […]
Read more

Concerted efforts required by both Indian pharma industry and government to boost innovation in India, says GlobalData

The Indian Pharmaceutical Alliance (IPA) has recently urged the government to set up a fund to boost technological innovation in the bio/pharma space. This push to promote innovation by creating a research ecosystem is important because the Indian pharmaceutical industry is set to grow from nearly US$31bn in 2018 to more than US$38.0bn by 2022, says GlobalData, […]
Read more

Global hidradenitis suppurativa market set to reach $1.81bn by 2028

The hidradenitis suppurativa (HS) market is expected to grow from $898m in 2018 to $1.81bn in 2028 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 7.2%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028’, states that […]
Read more
1 … 104 105 106 107 108 … 110